Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Matthew Kaplan maintains a Buy rating on UroGen Pharma (NASDAQ:URGN) and raises the price target from $48 to $53.5.
June 14, 2024 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ladenburg Thalmann analyst Matthew Kaplan maintains a Buy rating on UroGen Pharma and raises the price target from $48 to $53.5.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100